Document Detail

Hyaluronic Acid for the Treatment of Osteoarthritis in all Joints Except the Knee: What is the Current Evidence?
MedLine Citation:
PMID:  22385405     Owner:  NLM     Status:  In-Data-Review    
Background: The use of intra-articular hyaluronic acid (HA) is a well known treatment in patients with knee osteoarthritis (OA). In other joints, less evidence is available about the efficacy of treatment with intra-articular HA. HA is also used intra-articularly in the metatarsophalangeal-1 joint, the ankle, the hip, the sacroiliac joint, the facet joints, the carpometacarpal-1 joint, the shoulder and the temporo-mandibular joint. In this systematic review we include all prospective studies about the effects of intra-articular HA in the above-mentioned joints. Its use in the knee joint, however, will be discussed in a separate article in this journal. Methods: A systematic review was conducted using databases including MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Clinical Trial Register, and EMBASE. Results: After performing a solid systematic review using a rigid methodology and trying to pool the outcomes of different studies, we noticed that, compared with baseline, there is statistical evidence for a positive effect of intra-articular HA. However, there is limited evidence HA is superior to placebo and no evidence that intra-articular HA is better than corticosteroids or other conservative therapies. Conclusion: Our recommendation for future research is that one should focus on adequately powered randomized trials comparing HA treatment with other types of intra-articular or conservative treatment. We think it is useless to further perform and publish (large) non-comparative prospective studies about the use of HA in the treatment of problems caused by OA. It is well perceived that HA exerts positive effects in the treatment of OA, but up to now there is no (strong) evidence available that HA is superior to other treatments of OA such as corticosteroids, physiotherapy or other conservative measures.
Sascha Colen; Daniel Haverkamp; Michiel Mulier; Michel P J van den Bekerom
Related Documents :
22412055 - Impact of treatment strategy on outcomes in patients with candidemia and other forms of...
22365275 - The beck depression inventory and general health questionnaire as measures of depressio...
22734605 - Psychological correlates of early onset of ischemic heart disease in a sample drawn fro...
22454805 - Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medica...
9735575 - Axis ii symptomatology, depression, and life stress during the transition from adolesce...
22232535 - Short term outcomes of prostate biopsy in men tested for cancer by prostate specific an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  26     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  101-12     Citation Subset:  IM    
University Hospitals Leuven, Department of Orthopaedic Surgery, Pellenberg, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting the epidermal growth factor receptor in solid tumor malignancies.
Next Document:  How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in...